These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 25296997)

  • 1. Metabolic signatures of malignant and non-malignant mass-forming lesions in the periampulla and pancreas in FDG PET/CT scan: an atlas with pathologic correlation.
    Santhosh S; Mittal BR; Rana SS; Srinivasan R; Bhattacharya A; Das A; Bhasin D
    Abdom Imaging; 2015 Jun; 40(5):1285-315. PubMed ID: 25296997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
    Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
    J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypermetabolic lesions of the pancreas on FDG PET/CT.
    Dong A; Dong H; Zhang L; Zuo C
    Clin Nucl Med; 2013 Sep; 38(9):e354-66. PubMed ID: 23486316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of PET/CT for the differentiation and characterization of periampullary lesions.
    Cheng MF; Wang HP; Tien YW; Liu KL; Yen RF; Tzen KY; Wu YW
    Clin Nucl Med; 2013 Sep; 38(9):703-8. PubMed ID: 23816944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis and management of pancreatic cancer; comparison with multidetector row computed tomography, magnetic resonance imaging and endoscopic ultrasonography.
    Ergul N; Gundogan C; Tozlu M; Toprak H; Kadıoglu H; Aydin M; Cermik TF
    Rev Esp Med Nucl Imagen Mol; 2014; 33(3):159-64. PubMed ID: 24140024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benign nonphysiologic lesions with increased 18F-FDG uptake on PET/CT: characterization and incidence.
    Metser U; Miller E; Lerman H; Even-Sapir E
    AJR Am J Roentgenol; 2007 Nov; 189(5):1203-10. PubMed ID: 17954662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of FDG uptake in pancreatic non-Hodgkin's lymphoma lesions.
    Dong A; Cui Y; Gao L; Wang Y; Zuo C; Yang J
    Abdom Imaging; 2014 Feb; 39(1):175-86. PubMed ID: 24136586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the management of patients with nonpancreatic periampullary neoplasms.
    Sperti C; Pasquali C; Fiore V; Bissoli S; Chierichetti F; Liessi G; Pedrazzoli S
    Am J Surg; 2006 Jun; 191(6):743-8. PubMed ID: 16720142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT.
    Metser U; Even-Sapir E
    Semin Nucl Med; 2007 May; 37(3):206-22. PubMed ID: 17418153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis of pancreatic carcinoma: role of FDG PET.
    Keogan MT; Tyler D; Clark L; Branch MS; McDermott VG; DeLong DM; Coleman RE
    AJR Am J Roentgenol; 1998 Dec; 171(6):1565-70. PubMed ID: 9843289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of 18F-FDG PET/CT for differentiation of autoimmune pancreatitis with atypical pancreatic imaging findings from pancreatic cancer.
    Lee TY; Kim MH; Park DH; Seo DW; Lee SK; Kim JS; Lee KT
    AJR Am J Roentgenol; 2009 Aug; 193(2):343-8. PubMed ID: 19620430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of FDG-PET/CT in the detection of pancreatic metastases from lung cancer.
    Sato M; Okumura T; Kaito K; Kiyoshima M; Asato Y; Uchiumi K; Iijima H; Hashimoto I; Kaburagi T; Amemiya R
    Ann Nucl Med; 2009 Jan; 23(1):49-57. PubMed ID: 19205838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of F-18-FDG PET/CT findings between pancreatic solid pseudopapillary tumor and pancreatic ductal adenocarcinoma.
    Kim YI; Kim SK; Paeng JC; Lee HY
    Eur J Radiol; 2014 Jan; 83(1):231-5. PubMed ID: 24290142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG activitiy PET/CT and CA-19.9 levels for the prediction of histopathological features and localization of peri- ampullary tumors.
    Akcam AT; Ülkü A; Rencuzoğulları A; Parsak CK; Yapar Z; Doran F; Demiryürek H; Okoh AK
    Turk J Gastroenterol; 2015 Mar; 26(2):170-5. PubMed ID: 25835117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
    Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Semiquantitative Analysis of the Biodistribution of the Combined ¹⁸F-NaF and ¹⁸F-FDG Administration for PET/CT Imaging.
    Minamimoto R; Mosci C; Jamali M; Barkhodari A; Habte F; Jackson T; Mittra E; Gambhir SS; Iagaru A
    J Nucl Med; 2015 May; 56(5):688-94. PubMed ID: 25840978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT.
    Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E; Ebied O
    Eur J Radiol; 2009 Jun; 70(3):530-8. PubMed ID: 18395387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of 18F-FDG PET/CT in the evaluation of Ascites of Undetermined Origin.
    Zhang M; Jiang X; Zhang M; Xu H; Zhai G; Li B
    J Nucl Med; 2009 Apr; 50(4):506-12. PubMed ID: 19289438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.